REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants

by | Sep 30, 2026 | Clinical Trials | 0 comments

​ Conditions: Metastatic Castration-Resistant Prostate Cancer; mCRPC

Interventions: Drug: REGN21353; Drug: Nezastomig; Drug: Sarilumab Prophylaxis (Contingency)

Sponsors: Regeneron Pharmaceuticals

Not yet recruiting Conditions: Metastatic Castration-Resistant Prostate Cancer; mCRPC
Interventions: Drug: REGN21353; Drug: Nezastomig; Drug: Sarilumab Prophylaxis (Contingency)
Sponsors: Regeneron Pharmaceuticals
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *